Article Information
History
- January 13, 2023.
Article Versions
- Version 1 (January 12, 2023 - 10:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maja Di Rocco, MD, PhD1,
- Eduardo Forleo-Neto, MD2,#,
- Robert Pignolo, MD, PhD3,
- Richard Keen, PhD, FRCP4,
- Philippe Orcel, MD, PhD5,6,
- Thomas Funck-Brentano, MD, PhD5,6,
- Christian Roux, MD, PhD7,
- Sami Kolta, MD7,
- Annalisa Madeo, MD1,
- Judith S Bubbear, MD, FRCP4,
- Jacek Tabarkiewicz, MD, PhD8,
- Małgorzata Szczepanek, MD, PhD8,
- Javier Bachiller-Corral, MD9,
- Angela M Cheung, MD, PhD10,
- Kathryn M Dahir, MD11,
- Esmée Botman, MD, PhD12,
- Pieter G Raijmakers, MD, PhD13,
- Mona Al Mukaddam, MD14,
- Lianne Tile, MD10,
- Cynthia Portal-Celhay, MD, PhD2,
- Neena Sarkar, PhD2,
- Peijie Hou, PhD2,
- Bret Musser, PhD2,
- Anita Boyapati, PhD2,
- Kusha Mohammadi, PhD2,
- Scott Mellis, MD, PhD2,
- Andrew J. Rankin, PhD2,
- Aris N. Economides, PhD2,
- Dinko Gonzalez Trotter, PhD2,
- Gary Herman, MD2,
- Sarah J. O’Meara, PhD2,
- Richard DelGizzi, MS2,
- David M. Weinreich, MD2,
- George D. Yancopolous, MD, PhD2,
- E. Marelise W. Eekhoff, MD, PhD12,*,
- Frederick S. Kaplan, MD14,* and
- the LUMINA-1 Investigators
- 1Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 2Regeneron Pharmaceuticals, Tarrytown, NY, USA
- 3Department of Medicine, Mayo Clinic, Rochester, MN, USA
- 4Centre for Metabolic Bone Disease Royal National Orthopaedic Hospital NHS Trust, London, UK
- 5Department of Rheumatology-DMU Locomotion, Assistance Publique - Hôpitaux de Paris, Paris, France
- 6INSERM Université Paris Cité, Paris, France
- 7Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
- 8Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów University, Rzeszów, Podkarpackie, Poland
- 9Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 10University Health Network, University of Toronto, Toronto, ON, Canada
- 11Vanderbilt University Medical Center, Program for Metabolic Bone Disorders, Nashville, TN, USA
- 12Department of Internal Medicine Section of Endocrinology, Amsterdam UMC, Vrije Universiteit, Amsterdam Bone Center, Amsterdam, The Netherlands
- 13Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands
- 14Departments of Orthopaedics, Medicine and the Center for Research in FOP & Related Disorders, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- ↵#Corresponding author; email: eduardo.forleoneto{at}regeneron.com
Posted January 13, 2023.
Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
